ANGUS Chemical Company, a global manufacturer of specialty ingredients and consumables for biotechnology, pharmaceutical, consumer and industrial applications, plans to expand U.S. production capacity for its complete portfolio of TRIS AMINO™ tromethamine buffers. ANGUS is the largest and only fully integrated original manufacturer of TRIS AMINO buffers, which are used extensively in bioprocessing and diagnostics manufacturing, as building blocks for synthesis of surface-active agents and pharmaceuticals, among others.
 
The expansion includes the addition of a fourth dedicated manufacturing line at ANGUS’ existing facility in Sterlington, LA, and will roughly double the company’s global TRIS AMINO buffer production capacity. The company currently produces high-purity, multi-compendial grades of TRIS AMINO products for the life sciences and personal care markets at its Sterlington site and recently expanded Ibbenbüren, Germany manufacturing facilities. 
 
“This is a significant investment that highlights our commitment to continuously expanding our asset base and global manufacturing capabilities to support fast-growing demand for TRIS AMINO buffers across life sciences, personal care and industrial markets,” said David Neuberger, ANGUS President and Chief Executive Officer. “It not only supports the pursuit of our vision to position ANGUS as a leading global supplier of essential life sciences ingredients, but also further enhances the supply chain continuity and security of supply we provide to our customers for this essential chemistry.”
 
Between 2016 and 2021, ANGUS doubled TRIS AMINO production capacity. In 2020, the company completed the start-up of new TRIS AMINO™ AC Advanced Crystal continuous manufacturing capacity in Ibbenbüren, and opened its new, dedicated life sciences warehouse, quality control laboratory, and filling / packaging center in Sterlington. ANGUS’ production facilities in the U.S. and Germany are designed to the highest standards and include cGMP compliant manufacturing that adhere to current IPEC excipient guidelines.